



SASKATCHEWAN FORMULARY BULLETIN

Update to the 62nd Edition of the Saskatchewan Formulary

Product	DIN	Pre-Markup (\$)
----------------	------------	------------------------

New Exception Drug Status (EDS) Listing Effective May 1, 2014:

Tecfidera (dimethyl fumarate) (BGN)		
120mg delayed-release capsule	02404508	16.1925
240mg delayed-release capsule	02420201	32.3850

Approval for coverage will be given to patients who are assessed and meet the following criteria:

- have clinical definite relapsing and remitting multiple sclerosis;
- have had at least two documented attacks of MS during the previous two years (an attack is defined as the appearance of new symptoms or worsening of old symptoms, lasting at least 24 hours in the absence of fever, preceded by stability for at least one month);
- are fully ambulatory for 100 meters without aids (canes, walkers or wheelchairs)
- Extended Disability Status Scale (EDSS) 5.5 or less;
- are age 18 or older (Note: Applications for patients under 18 will be considered.)

Physicians should also forward the following information:

- documentation of attacks, date of onset, date of diagnosis;
- neurological findings, Extended Disability Status Scale (EDSS);
- MRI reports or other significant information;
- list of current medications.

**Saskatchewan Ministry of Health
Drug Plan and Extended Benefits Branch
2nd Floor, 3475 Albert Street
Regina, Saskatchewan S4S 6X6
(306) 787-3317
1-800-667-7581**

This Bulletin is not to be reproduced or republished except with the approval of the Saskatchewan Ministry of Health. Inquiries should be directed to the address or telephone numbers shown at left.